dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: Non-enzymatic BRD containing proteins (type: other_protein)
Target: SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2

Ligand: SMD-3040 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 8 pKd
Reference (Journal): Discovery of SMD-3040 as a Potent and Selective SMARCA2 PROTAC Degrader with Strong <i>in vivo</i> Antitumor Activity.
Published in: J Med Chem

Ligand: GNE-235 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 5.21999979019165 pKd
Reference (Journal): GNE-235: A Lead Compound Selective for the Second Bromodomain of PBRM1.
Published in: J Med Chem

Ligand: GNE-064 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.800000190734863 pIC50
Reference (Journal): GNE-064: A Potent, Selective, and Orally Bioavailable Chemical Probe for the Bromodomains of SMARCA2 and SMARCA4 and the Fifth Bromodomain of PBRM1.
Published in: J Med Chem

Ligand: A947 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.03000020980835 pKd
Reference (Journal): Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers.
Published in: Nat Commun
Target family: Non-enzymatic BRD containing proteins (type: other_protein)
Target: polybromo 1

Ligand: PFI-3 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 7.320000171661377 pKd
Reference (Webpage): PFI-3 A Selective chemical probe for SMARCA bromodomains.

Ligand: GNE-235 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 4.820000171661377 pKd
Reference (Journal): GNE-235: A Lead Compound Selective for the Second Bromodomain of PBRM1.
Published in: J Med Chem

Ligand: GNE-235 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 6.550000190734863 pKd
Reference (Journal): GNE-235: A Lead Compound Selective for the Second Bromodomain of PBRM1.
Published in: J Med Chem

Ligand: GNE-064 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.739999771118164 pIC50
Reference (Journal): GNE-064: A Potent, Selective, and Orally Bioavailable Chemical Probe for the Bromodomains of SMARCA2 and SMARCA4 and the Fifth Bromodomain of PBRM1.
Published in: J Med Chem
Target family: Non-enzymatic BRD containing proteins (type: other_protein)
Target: E1A binding protein p300

Ligand: TTK21 (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): A novel activator of CBP/p300 acetyltransferases promotes neurogenesis and extends memory duration in adult mice.
Published in: J Neurosci

Ligand: SGC-CBP30 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.420000076293945 pIC50
Reference (Journal): Bromodomains and their pharmacological inhibitors.
Published in: ChemMedChem

Ligand: plumbagin (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.599999904632568 pIC50
Reference (Journal): Inhibition of lysine acetyltransferase KAT3B/p300 activity by a naturally occurring hydroxynaphthoquinone, plumbagin.
Published in: J Biol Chem

Ligand: Lys-CoA (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.300000190734863 pIC50
Reference (Journal): HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF.
Published in: Mol Cell

Ligand: inobrodib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.71999979019165 pIC50
Reference (Journal): Targeting the p300/CBP Axis in Lethal Prostate Cancer.
Published in: Cancer Discov

Ligand: inobrodib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.770000457763672 pKd
Reference (Journal): Targeting the p300/CBP Axis in Lethal Prostate Cancer.
Published in: Cancer Discov
Target family: Notch receptors (type: other_protein)
Target: notch receptor 1

Ligand: brontictuzumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 8.359999656677246 pKd
Reference (Patent): Notch1 receptor binding agents and methods of use thereof
Target family: Notch receptors (type: other_protein)
Target: notch receptor 2

Ligand: tarextumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 10 pKd
Reference (Patent): Antibodies to notch receptors.

Ligand: Jagged2 (Peptide)
Interaction type: Agonist
Action: Activation
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Binding of Delta1, Jagged1, and Jagged2 to Notch2 rapidly induces cleavage, nuclear translocation, and hyperphosphorylation of Notch2.
Published in: Mol Cell Biol
Target family: Notch receptors (type: other_protein)
Target: notch receptor 1

Ligand: Jagged2 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Isolation and functional analysis of a cDNA for human Jagged2, a gene encoding a ligand for the Notch1 receptor.
Published in: Mol Cell Biol

Ligand: IMR-1 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 4.960000038146973 pKd
Reference (Journal): The Small Molecule IMR-1 Inhibits the Notch Transcriptional Activation Complex to Suppress Tumorigenesis.
Published in: Cancer Res
Target family: Notch receptors (type: other_protein)
Target: notch receptor 3

Ligand: tarextumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 9.920000076293945 pKd
Reference (Patent): Antibodies to notch receptors.
Target family: NuaK subfamily (type: enzyme)
Target: NUAK family kinase 1

Ligand: cerdulatinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.399999618530273 pIC50
Reference (Journal): The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.
Published in: J Pharmacol Exp Ther

Ligand: compound 25b [PMID: 22564207] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.590000152587891 pIC50
Reference (Journal): Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase.
Published in: J Med Chem

Ligand: HTH-01-015 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7 pIC50
Reference (Journal): Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases.
Published in: Biochem J

Ligand: HTH-02-006 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.100000381469727 pIC50
Reference (Journal): NUAK2 is a critical YAP target in liver cancer.
Published in: Nat Commun

Ligand: narazaciclib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.3100004196167 pIC50
Reference (Journal): Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5).
Published in: J Med Chem

Ligand: WZ4002 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.039999961853027 pKd
Reference (Journal): Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.
Published in: Nature

Ligand: WZ4003 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.699999809265137 pIC50
Reference (Journal): Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases.
Published in: Biochem J
Target family: NuaK subfamily (type: enzyme)
Target: NUAK family, SNF1-like kinase, 2

Ligand: HTH-02-006 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.900000095367432 pIC50
Reference (Journal): NUAK2 is a critical YAP target in liver cancer.
Published in: Nat Commun

Ligand: WZ4003 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7 pIC50
Reference (Journal): Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases.
Published in: Biochem J
Target family: Nuclear export proteins (type: other_protein)
Target: exportin 1

Ligand: eltanexor (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells.
Published in: Leukemia

Ligand: eltanexor (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies.
Published in: Leukemia

Ligand: eltanexor (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.
Published in: Clin Cancer Res

Ligand: selinexor (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2019), EMA (2021)
Primary target: no
Median affinity:  -
Reference (Patent): Nuclear transport modulators and uses thereof.
Target family: Nucleoside synthesis and metabolism (type: enzyme)
Target: dihydroorotate dehydrogenase (quinone)

Ligand: DSM421 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4 pIC50
Reference (Journal): A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria.
Published in: ACS Infect Dis
Target family: Nucleoside synthesis and metabolism (type: enzyme)
Target: xanthine dehydrogenase

Ligand: topiroxostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: febuxostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: EMA & FDA (2009)
Primary target: no
Median affinity: 8.899999618530273 pIC50
Reference (Journal): HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase.
Published in: Bioorg Med Chem Lett

Ligand: febuxostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: EMA & FDA (2009)
Primary target: yes
Median affinity: 9.920000076293945 pKi
Reference (Journal): An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition.
Published in: J Biol Chem

Ligand: febuxostat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: EMA & FDA (2009)
Primary target: yes
Median affinity: 7.519999980926514 pIC50
Reference (Journal): Isocytosine-based inhibitors of xanthine oxidase: design, synthesis, SAR, PK and in vivo efficacy in rat model of hyperuricemia.
Published in: Bioorg Med Chem Lett

Ligand: allopurinol (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1966), EMA (2018)
Primary target: yes
Median affinity: 5.150000095367432 pKi
Reference (Journal): Synthesis and biological evaluation of new imidazole, pyrimidine, and purine derivatives and analogs as inhibitors of xanthine oxidase.
Published in: J Med Chem

Ligand: allopurinol (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1966), EMA (2018)
Primary target: yes
Median affinity: 5.380000114440918 pIC50
Reference (Journal): Synthesis and biological evaluation of new imidazole, pyrimidine, and purine derivatives and analogs as inhibitors of xanthine oxidase.
Published in: J Med Chem
Target family: Nucleoside synthesis and metabolism (type: enzyme)
Target: thymidylate synthetase

Ligand: raltitrexed (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: EMA (2009)
Primary target: no
Median affinity: 6.380000114440918 pKi
Reference (Journal): Syntheses and thymidylate synthase inhibitory activity of the poly-gamma-glutamyl conjugates of N-[5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino ]-2-thenoyl]-L-glutamic acid (ICI D1694) and other quinazoline antifolates.
Published in: J Med Chem

Ligand: raltitrexed (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: EMA (2009)
Primary target: yes
Median affinity: 6.539999961853027 pIC50
Reference (Journal): Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents.
Published in: Bioorg Med Chem

Ligand: plevitrexed (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.359999656677246 pKi
Reference (Journal): Design and synthesis of potent non-polyglutamatable quinazoline antifolate thymidylate synthase inhibitors.
Published in: J Med Chem

Ligand: pemetrexed (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2004), EMA (2009)
Primary target: no
Median affinity: 6.960000038146973 pKi
Reference (Journal): Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).
Published in: Adv Enzyme Regul

Ligand: ONX-0801 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.920000076293945 pKi
Reference (Journal): BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors.
Published in: Cancer Res

Ligand: capecitabine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1998), EMA (2001)
Primary target: yes
Median affinity:  -
Reference (Journal): The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status.
Published in: Oncologist

Ligand: capecitabine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1998), EMA (2001)
Primary target: yes
Median affinity:  -
Reference (Journal): UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Published in: Clin Cancer Res
Target family: Nucleoside synthesis and metabolism (type: enzyme)
Target: ribonucleotide reductase regulatory subunit M2

Ligand: hydroxyurea (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1967), EMA (2007)
Primary target: yes
Median affinity: 3.8299999237060547 pIC50
Reference (Journal): Determination of the potency and subunit-selectivity of ribonucleotide reductase inhibitors with a recombinant-holoenzyme-based in vitro assay.
Published in: Biochem Pharmacol

Ligand: gemcitabine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1996)
Primary target: yes
Median affinity:  -
Reference (Journal): Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine.
Published in: Mol Pharmacol

Ligand: fludarabine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1991)
Primary target: yes
Median affinity: 6 pIC50
Reference (Journal): In vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells.
Published in: Mol Pharmacol

Ligand: clofarabine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2004), EMA (2009)
Primary target: yes
Median affinity: 8.300000190734863 pIC50
Reference (Journal): Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate.
Published in: Cancer Res
Target family: Nucleoside synthesis and metabolism (type: enzyme)
Target: ribonucleotide reductase catalytic subunit M1

Ligand: TAS1553 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.460000038146973 pKd
Reference (Journal): TAS1553, a small molecule subunit interaction inhibitor of ribonucleotide reductase, exhibits antitumor activity by causing DNA replication stress.
Published in: Commun Biol

Ligand: hydroxyurea (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1967), EMA (2007)
Primary target: yes
Median affinity: 3.8299999237060547 pIC50
Reference (Journal): Determination of the potency and subunit-selectivity of ribonucleotide reductase inhibitors with a recombinant-holoenzyme-based in vitro assay.
Published in: Biochem Pharmacol

Ligand: gemcitabine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1996)
Primary target: yes
Median affinity:  -
Reference (Journal): Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine.
Published in: Mol Pharmacol

Ligand: fludarabine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1991)
Primary target: yes
Median affinity: 6 pIC50
Reference (Journal): In vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells.
Published in: Mol Pharmacol

Ligand: clofarabine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2004), EMA (2009)
Primary target: no
Median affinity: 8.300000190734863 pIC50
Reference (Journal): Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate.
Published in: Cancer Res
Target family: Nucleoside synthesis and metabolism (type: enzyme)
Target: purine nucleoside phosphorylase

Ligand: forodesine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 10.140000343322754 pKi
Reference (Journal): One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase.
Published in: Biochemistry
Target family: Nucleoside synthesis and metabolism (type: enzyme)
Target: phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase

Ligand: pemetrexed (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2004), EMA (2009)
Primary target: no
Median affinity: 5.03000020980835 pKi
Reference (Journal): Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).
Published in: Adv Enzyme Regul
Target family: Nucleoside synthesis and metabolism (type: enzyme)
Target: inosine monophosphate dehydrogenase 2

Ligand: thioguanine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1966)
Primary target: yes
Median affinity:  -
Reference (Journal): Thioguanine, mercaptopurine: their analogs and nucleosides as antimetabolites.
Published in: Curr Pharm Des

Ligand: thioguanine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1966)
Primary target: yes
Median affinity:  -
Reference (Journal): IMP dehydrogenase basal activity in MOLT-4 human leukaemia cells is altered by mycophenolic acid and 6-thioguanosine.
Published in: Scand J Clin Lab Invest

Ligand: ribavirin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1985), EMA (1999)
Primary target: yes
Median affinity:  pIC50
Reference (Journal): Novel 1,2,4-triazole and imidazole derivatives of L-ascorbic and imino-ascorbic acid: synthesis, anti-HCV and antitumor activity evaluations.
Published in: Bioorg Med Chem

Ligand: mycophenolic acid (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2009)
Primary target: yes
Median affinity: 7.699999809265137 pIC50
Reference (Journal): Synthesis and immunosuppressive activity of some side-chain variants of mycophenolic acid.
Published in: J Med Chem

Ligand: mycophenolate mofetil (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1995), EMA (1996)
Primary target: yes
Median affinity:  -

Ligand: merimepodib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8 pIC50
Reference (Journal): Discovery of N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl-4- morpholineacetamide as a novel and potent inhibitor of inosine monophosphate dehydrogenase with excellent in vivo activity.
Published in: J Med Chem